Last updated: April 23, 2026
Risperidone supply is organized around (1) API manufacturers that produce risperidone (and sometimes key intermediates) and (2) contract manufacturers and formulators that turn API into marketed dosage forms. For business decisions on R&D sourcing, switch-and-supply planning, or pipeline risk, the actionable way to map suppliers is by identifying API manufacturers that make risperidone itself and by linking those to dosage-form sites listed in regulatory filings and quality systems.
Which companies manufacture risperidone API?
Risperidone API is supplied by multiple manufacturers with established global distribution, including Indian, Chinese, and European suppliers. In practice, the supplier set for any given buyer is constrained by regulatory status (DMF status, suitability for US/EU filings), site qualification, and audit outcomes.
Below are named risperidone API suppliers that have been publicly associated with risperidone manufacture or commercial supply in regulatory and industry sources.
Risperidone API suppliers (examples observed in public supply/regulatory databases)
| Supplier |
Market footprint |
Reported role |
Notes for procurement |
| Teva (API supply and global manufacturing network) |
Global |
API and finished-dose supply |
Used widely across geographies through brand and generic supply chains. |
| Sun Pharmaceutical Industries |
Global |
API and/or contract supply |
Large-scale generics and API integration. |
| Mylan (now part of Viatris) |
Global |
Generic supply chain |
Operates through portfolio manufacturing and supplier network. |
| Sandoz |
Global |
Generic supply chain |
Uses integrated and external manufacturing. |
| Zhejiang NHU (via NHU formulations and chemical supply chain) |
China/Global |
Chemical supply network |
Commonly appears in generic supply ecosystems; risk-managed via site qualification. |
| Accord Healthcare (global generics supply) |
UK/EU/Global |
Finished dosage and procurement network |
Works through API sourcing and contract manufacturing partners. |
| Dr. Reddy’s Laboratories |
Global |
API and finished dose |
Strong API manufacturing and export capability. |
Procurement reality: buyers typically do not purchase “API only” from the same supplier that distributes the finished product. They buy API from DMF-qualified manufacturers and then contract to a dosage-form manufacturer, or they buy the finished dose from a branded/generic company that has already validated supply.
Which suppliers make risperidone finished dosage forms?
Risperidone is marketed as both branded and generic products. Finished-dosage supply typically involves tablets, orally disintegrating tablets, oral solutions, and long-acting injectable products (LAIs), depending on the country and product line. LAIs create a more supplier-limited environment because of sterile manufacturing and complex formulation.
Finished dosage suppliers (examples)
| Company |
Typical product positioning |
What it implies for buyers |
| Janssen / Johnson & Johnson |
Branded originator portfolio |
Strong regulatory and quality presence for originator product forms. |
| Teva |
Generic and biosimilar-adjacent manufacturing network |
Broad coverage of oral formulations and supply depth. |
| Viatris |
Global generics |
Often supplies tablets and other oral presentations. |
| Sandoz |
Global generics |
EU and broader distribution. |
| Accord |
UK/EU footprint |
Often supplies EU-focused generics. |
How to screen risperidone API suppliers for qualification risk
Risperidone is a well-established antipsychotic with broad generic competition, but qualification risk still turns on regulatory evidence and manufacturing controls. For supply continuity and compliance, buyers should screen suppliers against:
- Regulatory file readiness
- US DMF status (Type II, if applicable to the supplier’s system) and whether the site has history of approvals.
- EU dossier coverage (where relevant) for risperidone API.
- GMP status by site
- Inspection outcomes and remediation history.
- Sterility/aseptic capability only matters for LAIs, not for API or oral forms.
- Quality documentation
- CoA trend data for critical quality attributes (assay, impurities profile, residual solvents).
- Change control stability (typical lead time and notification adherence).
- Synthetic route control
- Confirmation of consistent impurity profile and ability to match established specs in existing formulations.
What are the key intermediate and chemistry supply considerations?
Risperidone API manufacture depends on controlled access to chemical intermediates and consistent impurity management. For buyers, this is a risk lens:
- Route reproducibility: suppliers must demonstrate repeatability of impurity profile and polymorphic form control (if applicable to their process).
- Impurity strategy: risperidone has known impurity controls tied to regulatory expectations for generic quality.
- Solvent and reagent supply: supply interruptions often come from reagent availability, not from API core capacity.
Which supplier models dominate the risperidone market?
Risperidone supply typically follows one or more of these models:
- Integrated API and dosage manufacturing
Some companies manufacture both API and finished doses or maintain contracted dosage capacity tightly aligned with their API.
- API supplier plus contract manufacturer
Buyers source API from an API specialist and use a separate contract manufacturer for tablets or solutions.
- Finished-dose purchase with API behind the curtain
Many generics buyers and hospital formularies buy finished product, with API sourcing handled by the finished-dose marketer.
What does this mean for R&D sourcing and investment risk?
For an R&D program, the main supplier question is not “who sells risperidone” but “who can supply a qualification-grade API on schedule with documented comparability.” For investors and pipeline teams, risk centers on:
- API qualification timeline if switching suppliers.
- Impurity drift risk over time (process changes and catalyst/reagent changes).
- LAI complexity if the target includes long-acting formulations, which are far less interchangeable across supplier networks.
Key Takeaways
- Risperidone supply is broad at the finished-dose level and more controlled at the API quality and regulatory file level.
- API qualification and impurity profile stability are the decisive procurement factors, not raw availability.
- LAI supply is materially harder than oral form supply because sterile manufacturing and formulation know-how concentrate supplier eligibility.
- Supplier screening should focus on regulatory file readiness, site GMP outcomes, CoA trendability, and change-control discipline.
FAQs
-
Can a finished-dose supplier and an API supplier be different entities for risperidone?
Yes. Many marketers buy API from specialized API producers and contract or own dosage-form manufacturing.
-
Is risperidone API supply concentrated in one region?
No. Supply comes from multiple geographies including India, China, and Europe through different manufacturing models.
-
What qualification documents matter most when switching risperidone API sources?
CoA trend data, impurity profiles, residual solvent results, and evidence of consistent specifications over time.
-
Do the same suppliers typically handle long-acting injectable risperidone?
No. LAIs require sterile, complex formulation capabilities that reduce the supplier pool.
-
What is the fastest way to de-risk risperidone sourcing for a generic or development program?
Use an API supplier with established regulatory file readiness and a stable manufacturing site with documented change control.
References
[1] FDA. (n.d.). Drug Master Files (DMF). https://www.fda.gov/drugs/drug-master-files-dmf
[2] European Medicines Agency. (n.d.). Dossier and regulatory information. https://www.ema.europa.eu/
[3] Teva Pharmaceuticals. (n.d.). Company and manufacturing information. https://www.tevapharm.com/
[4] Sun Pharmaceutical Industries. (n.d.). Company information and manufacturing. https://www.sunpharma.com/
[5] Dr. Reddy’s Laboratories. (n.d.). Manufacturing and company information. https://www.drreddys.com/
